Biotechnology firm Galapagos receives offers for cell-therapy business
01/10/2025 21:11
Oct 1 (Reuters) - Biotechnology firm Galapagos' GLPG.AS board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday. (Reporting by Chandni Shah in Bengaluru; Editing by Alan Barona) ((Chandni.shah@thomsonreuters.com))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors